Fact-checked by Grok 2 weeks ago

Hyperphosphatemia

Hyperphosphatemia is an electrolyte disorder defined by elevated serum phosphate levels, typically exceeding 4.5 mg/dL in adults (normal range: 2.5–4.5 mg/dL), resulting from either excessive phosphate intake or reduced renal excretion.^[1] This condition is most prevalent in patients with chronic kidney disease (CKD), particularly in stages 4 and 5 where glomerular filtration rate falls below 30 mL/min, impairing the kidneys' ability to filter and excrete phosphate.^[2] While phosphate is essential for bone health, energy metabolism, and cellular function, its accumulation disrupts calcium-phosphate homeostasis, often leading to secondary hyperparathyroidism and increased cardiovascular risk.^[1] The primary cause of hyperphosphatemia is CKD, affecting up to 80% of patients with end-stage renal disease on dialysis, as the kidneys normally excrete 90% of dietary phosphate.^[2] Other etiologies include acute kidney injury, massive cell lysis from conditions like tumor lysis syndrome or rhabdomyolysis, excessive exogenous phosphate administration (e.g., from laxatives or enemas), and endocrine disorders such as hypoparathyroidism or tumoral calcinosis.^[1] In rare cases, genetic mutations leading to pseudohypoparathyroidism or familial tumoral calcinosis contribute by impairing phosphate regulation.^[1] Vitamin D intoxication can also elevate phosphate by enhancing gastrointestinal absorption.^[1] Clinically, hyperphosphatemia is frequently asymptomatic, especially in early stages, but severe or chronic cases may manifest with symptoms of associated hypocalcemia, including muscle cramps, tetany, paresthesias, seizures, or prolonged QT interval on electrocardiogram.^[1] Complications arise from metastatic calcification in soft tissues, vessels, and organs, promoting vascular stiffness, coronary artery disease, and increased mortality in CKD patients—where hyperphosphatemia independently significantly increases cardiovascular event risk. It also contributes to renal osteodystrophy, characterized by bone pain, fractures, and pruritus due to secondary hyperparathyroidism and mineral metabolism derangements.^[2] Diagnosis involves confirming elevated serum phosphate via repeated blood tests, alongside evaluation of renal function (e.g., serum creatinine, eGFR), calcium levels, parathyroid hormone (PTH), and vitamin D to identify underlying causes.^[1] In acute settings, markers for rhabdomyolysis (e.g., creatine kinase) or tumor lysis (e.g., uric acid, lactate dehydrogenase) may be assessed.^[1] Management focuses on treating the root cause; for CKD-related cases, strategies include dietary phosphate restriction to 800–1,000 mg/day (avoiding high-phosphate foods like dairy and processed items), oral phosphate binders (e.g., sevelamer or calcium acetate) to reduce absorption, and newer agents such as tenapanor, a sodium/hydrogen exchanger 3 inhibitor that reduces intestinal phosphate absorption, as well as intensified dialysis to enhance clearance.^[2]^[3] In severe acute hyperphosphatemia, intravenous hydration, loop diuretics, or emergent hemodialysis may be required to prevent life-threatening complications.^[1]

Background

Definition

Hyperphosphatemia is an electrolyte imbalance defined as an elevated serum phosphate concentration exceeding the normal range, typically greater than 4.5 mg/dL (1.45 mmol/L) in adults, though thresholds may vary slightly by laboratory standards and some guidelines use greater than 5 mg/dL (1.6 mmol/L) as the cutoff for clinical significance.^[1]^[4]^[5] The normal serum phosphate range for adults is 2.5–4.5 mg/dL (0.81–1.45 mmol/L), with higher levels in children (typically 4.0–7.0 mg/dL) due to growth demands and slightly lower values in the elderly owing to age-related declines in renal function and bone turnover.^[1]^[6]^[7] Hyperphosphatemia is classified as acute or chronic based on onset and underlying mechanisms. Acute hyperphosphatemia involves sudden elevation, often from iatrogenic causes such as excessive phosphate administration or massive endogenous release (e.g., tumor lysis), leading to rapid shifts in serum levels.^[4]^[8] In contrast, chronic hyperphosphatemia develops gradually, most commonly associated with progressive renal dysfunction where impaired excretion sustains elevated levels over time.^[1]^[9] The condition was first described in relation to renal failure and bone disease (renal osteodystrophy) in the early 20th century, with "renal rickets" linked to kidney disorders as early as 1883, though the specific role of phosphate retention gained prominence through mid-20th-century studies; modern thresholds were refined by nephrology guidelines emerging in the 1970s amid advancing understanding of chronic kidney disease.^[10]

Phosphate Homeostasis

Phosphate plays critical roles in cellular function and structural integrity, serving as a key component in the synthesis of adenosine triphosphate (ATP) for energy metabolism, deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) for genetic material, phospholipids in cell membranes, and hydroxyapatite in bone mineralization.^[11]^[12] Approximately 85% of total body phosphate is stored in the skeleton, with the remainder distributed intracellularly and in extracellular fluids to support these processes.^[11]^[13] The primary organs regulating phosphate homeostasis are the kidneys, intestines, and bones. In the kidneys, approximately 80-90% of the filtered phosphate load is reabsorbed in the proximal convoluted tubule via sodium-dependent phosphate cotransporters, primarily NaPi-IIa (encoded by SLC34A1).^[11]^[12]^[13] Intestinal absorption occurs mainly in the jejunum and ileum through both paracellular passive diffusion and active transcellular transport mediated by NaPi-IIb cotransporters, with bones acting as a dynamic reservoir where osteoblasts promote mineralization and osteoclasts facilitate release during resorption.^[11]^[12]^[13] Hormonal regulation tightly controls phosphate balance to maintain serum levels between 2.5 and 4.5 mg/dL. Parathyroid hormone (PTH), secreted by the parathyroid glands in response to low serum calcium, inhibits renal phosphate reabsorption by downregulating NaPi-IIa and NaPi-IIc transporters, thereby promoting phosphaturia, while also stimulating bone resorption to release phosphate from skeletal stores.^[11]^[13] Fibroblast growth factor 23 (FGF23), primarily produced by osteocytes in bone, suppresses renal phosphate reabsorption through similar downregulation of proximal tubular transporters and inhibits intestinal absorption indirectly by reducing 1,25-dihydroxyvitamin D synthesis.^[11]^[12]^[13] In contrast, 1,25-dihydroxyvitamin D enhances intestinal phosphate absorption by upregulating NaPi-IIb expression in enterocytes.^[11]^[13] Daily phosphate intake from diet typically ranges from 800 to 1500 mg, with 60-70% absorbed in the gastrointestinal tract under normal conditions.^[11]^[12] In healthy individuals, urinary excretion closely matches net absorption to maintain balance, averaging around 900-1000 mg per day, with minimal fecal losses.^[11]^[13] Renal handling of phosphate is quantified by the fractional excretion of phosphate (FEP), calculated as:

\text{FEP} = \left( \frac{\text{Urine PO}_4 / \text{Plasma PO}_4}{\text{Urine Cr} / \text{Plasma Cr}} \right) \times 100\%

Normal FEP values range from 5% to 20%, reflecting the balance between filtration, reabsorption, and excretion.^[11]^[13]

Etiology

Decreased Excretion

Decreased excretion of phosphate primarily occurs due to impaired renal function, as the kidneys are responsible for the majority of phosphate elimination through glomerular filtration and tubular reabsorption regulation. In chronic kidney disease (CKD) stages 4 and 5, where the glomerular filtration rate (GFR) falls below 30 mL/min/1.73 m², phosphate clearance diminishes significantly, leading to retention and hyperphosphatemia.^[1] The prevalence of hyperphosphatemia increases with CKD stage, from approximately 30-40% in stage 3 to over 60% in stages 4 and 5, affecting a substantial portion of patients with advanced CKD, particularly in end-stage renal disease (ESRD), where hyperphosphatemia prevalence ranges from 50% to 74%.^[1]^[14] Acute kidney injury (AKI) also contributes to decreased phosphate excretion by abruptly reducing GFR, resulting in sudden phosphate retention. Common etiologies of AKI include renal ischemia, exposure to nephrotoxic agents such as aminoglycosides or contrast media, and urinary tract obstruction, all of which compromise the kidney's ability to filter phosphate effectively.^[1] In hospitalized patients without ESRD, hyperphosphatemia associated with AKI occurs in approximately 12% of cases at admission.^[1] Endocrine disorders like hypoparathyroidism and pseudohypoparathyroidism impair phosphate excretion by disrupting parathyroid hormone (PTH)-mediated phosphaturia. In hypoparathyroidism, reduced PTH levels fail to inhibit renal phosphate reabsorption in the proximal tubule, promoting hyperphosphatemia.^[1] Similarly, pseudohypoparathyroidism involves end-organ resistance to PTH, leading to decreased urinary phosphate excretion despite normal or elevated PTH concentrations.^[1] Tumoral calcinosis, a rare genetic disorder, arises from deficiencies in fibroblast growth factor 23 (FGF23) or related proteins such as GALNT3, which normally suppress renal phosphate reabsorption. This results in enhanced tubular phosphate uptake and persistent hyperphosphatemia, often accompanied by ectopic calcifications.^[15] Certain medications can exacerbate decreased excretion, particularly in patients with underlying renal impairment. Phosphate-containing laxatives, such as Fleet enemas (sodium phosphate), deliver a high exogenous phosphate load that overwhelms compromised renal clearance, causing acute hyperphosphatemia and potential hypocalcemia.^[16] The Kidney Disease: Improving Global Outcomes (KDIGO) guidelines emphasize monitoring phosphate levels in CKD patients to manage such iatrogenic risks.^[17]

Increased Load or Redistribution

Increased load or redistribution of phosphate refers to mechanisms where phosphate enters the extracellular space in excess of normal homeostasis, either from external administration or internal mobilization, leading to elevated serum levels. This category primarily encompasses acute processes driven by rapid influx rather than sustained retention, distinguishing it from chronic dysregulation. Such elevations can overwhelm physiological buffering, particularly if compounded by impaired clearance, though the primary driver here is the influx itself.^[1] Exogenous phosphate load occurs when intake exceeds the body's capacity for absorption and utilization, often iatrogenically through oral or intravenous routes. In the context of refeeding malnourished patients, excessive phosphate administration as part of nutritional support can contribute to hyperphosphatemia, especially in severe cases of anorexia nervosa where late-phase elevations affect over 80% of individuals during recovery. Tumor lysis syndrome represents a classic endogenous overload from rapid cell destruction, particularly in hematologic malignancies such as acute lymphoblastic leukemia (ALL), where phosphate release from lysed tumor cells commonly results in serum levels exceeding 6.5 mg/dL (2.1 mmol/L) within 24 to 48 hours of initiating chemotherapy. This is attributed to the high intracellular phosphate content in rapidly proliferating malignant cells.^[18]^[19]^[20] Internal redistribution from tissue breakdown similarly floods the bloodstream with intracellular phosphate stores. Rhabdomyolysis, involving skeletal muscle necrosis, releases substantial phosphate quantities, leading to marked hyperphosphatemia in severe cases, often alongside myoglobinuria and potential for levels approaching 10 mmol/L or higher without concurrent renal complications. Hemolysis, the rupture of red blood cells, causes analogous phosphate efflux due to the anion's abundance within erythrocytes, contributing to acute elevations in conditions like massive intravascular hemolysis. Crush injuries, often entailing compartment syndrome and muscle trauma, provoke similar intracellular release through rhabdomyolysis-like mechanisms, exacerbating phosphate load in trauma settings.^[1]^[21]^[22] Redistribution without overt tissue destruction can also elevate serum phosphate via pH-dependent shifts. In metabolic acidosis, such as diabetic ketoacidosis (DKA), hydrogen ions enter cells, prompting phosphate to move extracellularly to maintain electroneutrality, thereby increasing plasma concentrations despite underlying total body depletion. Respiratory acidosis similarly drives this outward shift, as seen in conditions with CO2 retention, where acidosis promotes phosphate egress from intracellular compartments. These mechanisms highlight the role of acid-base disturbances in transient hyperphosphatemia.^[1]^[21]^[23] Iatrogenic causes, particularly phosphate-containing enemas used for constipation relief, pose a significant risk of acute overload, especially in vulnerable patients. These preparations can lead to severe hyperphosphatemia when retained, as the phosphate is absorbed systemically, with cases reported of fatal electrolyte derangements in those with underlying vulnerabilities.^[24]^[25]^[26] Hyperphosphatemia from increased load or redistribution is predominantly acute, arising rapidly from the precipitating event and typically resolving upon removal of the underlying cause, in contrast to chronic forms driven by persistent imbalances. This acuity underscores the importance of early recognition in high-risk scenarios like oncologic therapy or trauma.^[1]^[4]

Pathophysiology

Biochemical Effects

Elevated serum phosphate levels in hyperphosphatemia directly contribute to hypocalcemia by promoting the formation of calcium-phosphate complexes, which precipitate and reduce the availability of ionized calcium in the extracellular fluid.^[1] This acute drop in ionized calcium serves as a potent stimulus for the release of parathyroid hormone (PTH) from the parathyroid glands, initiating a compensatory endocrine response to restore calcium homeostasis.^[27] Chronic hyperphosphatemia sustains this hypocalcemic state, leading to secondary hyperparathyroidism characterized by parathyroid gland hyperplasia and persistently elevated PTH levels, often exceeding 300 pg/mL in advanced cases associated with chronic kidney disease (CKD).^[28] The hyperphosphatemia itself acts as a direct secretagogue for PTH, independent of calcium levels, exacerbating glandular overstimulation and contributing to long-term dysregulation of mineral metabolism.^[29] In response to high phosphate, the hormone fibroblast growth factor 23 (FGF23), primarily secreted by osteocytes, is upregulated to enhance renal phosphate excretion; however, this elevation suppresses the activity of 1α-hydroxylase in the kidney, thereby reducing production of the active vitamin D metabolite 1,25-dihydroxyvitamin D [1,25(OH)₂D].^[30] The resulting vitamin D deficiency impairs intestinal calcium and phosphate absorption, creating a feedback loop that worsens hypocalcemia and perpetuates hyperphosphatemia.^[31] At the cellular level, excess phosphate induces endothelial dysfunction in vascular smooth muscle through upregulation of the sodium-dependent phosphate transporter PiT-1 (also known as SLC20A1), which facilitates phosphate influx and triggers oxidative stress, inflammation, and apoptosis in endothelial cells.^[32] This molecular pathway promotes vascular stiffness and lays the groundwork for pathological remodeling without directly causing overt tissue damage.^[33] A key biochemical marker of these disruptions is the calcium-phosphate product, calculated as:

\text{Ca (mg/dL)} \times \text{PO}_4 \text{(mg/dL)}

Values greater than 55–70 mg²/dL² signal an elevated risk of ectopic calcification due to supersaturation and precipitation of calcium-phosphate salts.^[22] Recent studies as of 2025 have further elucidated that hyperphosphatemia in CKD is closely linked to klotho deficiency, where reduced expression of this anti-aging protein impairs FGF23 signaling, exacerbates phosphate retention, and accelerates vascular changes resembling premature aging, such as endothelial senescence and fibrosis.^[34]

Tissue and Organ Impacts

Hyperphosphatemia promotes ectopic calcification, particularly metastatic calcification in soft tissues such as the lungs and kidneys, when the calcium-phosphate product exceeds 70 mg²/dL².^[35] This occurs due to the precipitation of calcium phosphate crystals in normal tissues, driven by elevated serum phosphate levels that overwhelm inhibitory mechanisms like fetuin-A.^[36] In the kidneys, such deposits exacerbate renal dysfunction in chronic kidney disease (CKD) by further impairing phosphate excretion and contributing to nephrocalcinosis.^[1] Similarly, pulmonary metastatic calcification arises from hyperphosphatemia in end-stage renal disease, leading to calcium deposits in alveolar septa and vessels.^[37] Medial vascular calcification in arteries is another key pathological feature, where hyperphosphatemia induces vascular smooth muscle cells to adopt an osteochondrogenic phenotype, resulting in extracellular matrix mineralization.^[38] This process is mediated by sodium-dependent phosphate cotransporters like Pit-1, promoting hydroxyapatite crystal formation along the arterial media and leading to arterial stiffness and reduced compliance.^[38] In CKD patients, this calcification is prevalent and correlates with increased cardiovascular morbidity.^[39] In bone, chronic hyperphosphatemia contributes to high-turnover osteodystrophy through secondary hyperparathyroidism, where excess parathyroid hormone (PTH) drives osteoclast-mediated bone resorption and cortical porosity, ultimately causing bone fragility and increased fracture risk.^[40] Elevated PTH levels, stimulated by phosphate retention and hypocalcemia, lead to excessive bone remodeling, manifesting as osteitis fibrosa with fibrous replacement of marrow and potential formation of brown tumors.^[40] Cardiovascular impacts extend to accelerated atherosclerosis, where hyperphosphatemia fosters endothelial dysfunction and plaque progression via inflammatory pathways and oxidative stress.^[39] A meta-analysis of observational studies in CKD patients demonstrated that serum phosphate levels above 4.5 mg/dL are associated with a 57% increased risk of cardiovascular death, highlighting the role in myocardial infarction and heart failure.^[41] Pulmonary complications in severe chronic hyperphosphatemia include calcific deposits in the lung parenchyma, which can impair gas exchange by stiffening alveolar walls and promoting fibrosis in CKD patients on dialysis.^[37] Neurological effects are rare but include encephalopathy secondary to hypocalcemia-induced tetany, where acute phosphate elevation precipitates calcium, leading to neuromuscular irritability, seizures, and altered mental status.^[1] Histologically, chronic hyperphosphatemia results in the deposition of calcium phosphate crystals in soft tissues, appearing as basophilic aggregates on hematoxylin-eosin staining and confirming via von Kossa staining for phosphate.^[42] These crystals trigger local inflammation and cellular transdifferentiation, exacerbating tissue damage.^[43]

Clinical Features

Symptoms

Hyperphosphatemia is frequently asymptomatic, particularly in mild cases with serum phosphate levels below 6 mg/dL and in chronic presentations associated with gradual progression in chronic kidney disease.^[1]^[5] A common subjective complaint is pruritus, or severe itching, which arises from secondary hyperparathyroidism and uremic toxins in the context of elevated phosphate levels; this affects approximately 40–60% of patients on dialysis, often worsening sleep and quality of life.^[44] Patients may report bone and joint pain, stemming from renal osteodystrophy where high phosphate promotes abnormal bone remodeling and calcium pyrophosphate deposition, sometimes mimicking inflammatory arthritis with aching in the limbs and spine.^[45]^[40] Muscle weakness and cramps are also described, primarily as a consequence of concurrent hypocalcemia induced by phosphate binding to calcium, leading to sensations of fatigue and involuntary contractions in the extremities.^[46]^[47] In acute severe hyperphosphatemia exceeding 10 mg/dL, individuals often experience nausea, vomiting, and profound fatigue due to widespread metabolic disruptions including hypocalcemia and tissue calcification.^[48]^[49] Gastrointestinal symptoms such as diarrhea can occur in cases of phosphate overload from excessive intake, contributing to abdominal discomfort and dehydration.^[50]

Signs

Hyperphosphatemia often manifests through objective clinical signs primarily arising from associated hypocalcemia or chronic complications in patients with chronic kidney disease (CKD). In acute cases, hypocalcemia induced by elevated phosphate levels can lead to neuromuscular irritability, presenting as tetany, which involves sustained muscle contractions. Specific elicitable signs include Chvostek's sign, characterized by ipsilateral facial muscle twitching upon tapping the facial nerve anterior to the ear, and Trousseau's sign, where carpal spasm occurs after inflating a blood pressure cuff above systolic pressure for 3 minutes. These signs reflect latent tetany due to hypocalcemia secondary to phosphate binding of calcium.^[1]^[51] Skin findings in severe hyperphosphatemia, particularly within the context of advanced uremia from CKD, are uncommon but notable. More commonly associated with hyperphosphatemia is calciphylaxis, presenting as painful, necrotic skin ulcers with livedo reticularis or indurated plaques, often on the lower extremities, due to medial calcification of small arteries in CKD. This condition affects 1–4% of patients on dialysis.^[52]^[53] Cardiovascular signs stem from vascular and electrolyte disturbances. Chronic hyperphosphatemia promotes vascular stiffness through calcification of arterial media, contributing to hypertension as a measurable elevation in blood pressure. Acute electrolyte shifts, including hypocalcemia and hyperkalemia, can precipitate arrhythmias, such as prolonged QT interval or ventricular ectopy, observable on electrocardiography. Vital signs in acute hyperphosphatemia may include tachycardia, reflecting sympathetic activation or direct cardiac effects from phosphate toxicity.^[32]^[54] In chronic settings, skeletal manifestations arise from renal osteodystrophy, where persistent hyperphosphatemia drives secondary hyperparathyroidism and bone remodeling abnormalities. Clinicians may observe pathologic fractures, often of the ribs, vertebrae, or long bones, due to high-turnover bone disease, or deformities such as kyphoscoliosis from repeated fractures and chest wall collapse. Ocular examination can reveal band keratopathy, an opaque, horizontal band of calcium phosphate deposition in the superficial cornea, linked to elevated serum phosphate in CKD patients.^[55]^[56]

Diagnosis

Laboratory Assessment

The primary laboratory test for diagnosing hyperphosphatemia is measurement of serum phosphate concentration, with levels exceeding 4.5 mg/dL (1.45 mmol/L) in adults considered diagnostic, while normal ranges are typically 2.5-4.5 mg/dL (0.81-1.45 mmol/L); in children, the upper limit is higher at approximately 6 mg/dL due to growth-related demands.^[57] Serum phosphate should be interpreted alongside albumin-adjusted serum calcium levels, as hypocalcemia often accompanies hyperphosphatemia in renal causes, and the calcium-phosphate product (calculated as [calcium in mg/dL] × [phosphate in mg/dL]) exceeding 55 mg²/dL² indicates increased risk for soft tissue calcification.^[1] Associated laboratory findings provide context for etiology and severity. Hypocalcemia (serum calcium <8.5 mg/dL) is common in chronic kidney disease (CKD)-related hyperphosphatemia due to phosphate's inhibitory effect on hydroxylation of 25-hydroxyvitamin D.^[1] Elevated parathyroid hormone (PTH) levels, often >65 pg/mL, signal secondary hyperparathyroidism in response to hypocalcemia and phosphate retention, while serum creatinine >1.2 mg/dL (or estimated glomerular filtration rate <60 mL/min/1.73 m²) confirms underlying renal impairment as the most frequent cause.^[1]^[57] Urine phosphate assessment helps differentiate causes: 24-hour urinary phosphate excretion <0.5 g/day (or fractional excretion of phosphate <5%) indicates reduced renal excretion, as seen in CKD or hypoparathyroidism, whereas levels >1 g/day suggest increased phosphate load from dietary excess, tumor lysis, or rhabdomyolysis.^[57] A complete blood count (CBC) may reveal anemia (hemoglobin <11 g/dL) in the context of advanced CKD-associated hyperphosphatemia, reflecting erythropoietin deficiency and bone marrow fibrosis from secondary hyperparathyroidism.^[1] In acute settings like tumor lysis syndrome, CBC can show leukocytosis or lymphocytosis from underlying malignancy, alongside elevated lactate dehydrogenase (>2× upper limit of normal) and hyperkalemia (>5.5 mEq/L) as concurrent metabolic derangements.^[19] Measurement of fibroblast growth factor 23 (FGF23) is recommended primarily in research contexts for prognostic assessment, as elevated levels (>100 pg/mL) independently predict cardiovascular mortality and CKD progression in hyperphosphatemic patients.^[58]^[59]

Additional Investigations

In the diagnosis of hyperphosphatemia, imaging modalities play a key role in identifying associated complications such as ectopic calcifications. Plain X-ray radiography is commonly used to detect soft tissue calcifications, which can manifest as metastatic deposits in periarticular regions or other sites exposed to trauma, particularly in conditions like hyperphosphatemic familial tumoral calcinosis or chronic kidney disease (CKD).^[1]^[60] Computed tomography (CT) and magnetic resonance imaging (MRI) are employed to evaluate vascular calcifications, with non-contrast CT providing quantitative assessment via the Agatston score for coronary artery calcium; scores exceeding 100 are associated with elevated cardiovascular risk in CKD patients with hyperphosphatemia.^[61]^[62] Bone biopsy, though rarely performed due to its invasiveness, serves as the gold standard for histopathological confirmation of renal osteodystrophy in unclear cases of CKD-mineral bone disorder (CKD-MBD), such as osteitis fibrosa characterized by high bone turnover from secondary hyperparathyroidism exacerbated by hyperphosphatemia.^[40]^[63] Phosphate concentrations are reported in milligrams per deciliter (mg/dL) as the standard in the United States or millimoles per liter (mmol/L) in the International System of Units (SI), with conversion achieved by dividing mg/dL values by approximately 3.1 to obtain mmol/L.^[64] Pediatric reference ranges differ from adults, with neonates typically exhibiting higher levels of 4.0–7.0 mg/dL to support rapid growth and bone mineralization.^[65] Electrocardiography (ECG) is indicated to assess for cardiac arrhythmias secondary to concurrent hypocalcemia, a frequent accompaniment of hyperphosphatemia, which prolongs the QT interval primarily through ST segment lengthening and increases the risk of torsades de pointes.^[66]^[67] To aid in differential diagnosis, clinicians should consider pseudohyperphosphatemia, an analytical artifact where paraproteins in multiple myeloma interfere with colorimetric phosphate assays, leading to falsely elevated readings that do not reflect true hyperphosphatemia; confirmation involves alternative assay methods or direct measurement of ionized phosphate.^[68]^[69] Recent 2024 updates in CKD-MBD guidelines emphasize the role of dual-energy X-ray absorptiometry (DXA) for evaluating bone mineral density in chronic hyperphosphatemia cases, particularly to distinguish adynamic bone disease from osteoporosis and guide fracture risk assessment, though interpretation requires integration with biochemical markers due to altered bone turnover.^[70]^[71]

Management

Acute Interventions

In acute hyperphosphatemia, particularly when severe (serum phosphate >10 mg/dL) or symptomatic, the primary goal is to rapidly lower phosphate levels while addressing the underlying cause, such as acute kidney injury (AKI) or massive phosphate load.^[72] Initial interventions prioritize enhancing phosphate excretion, removing exogenous sources, and stabilizing associated electrolyte imbalances like hypocalcemia.^[1] Volume expansion with intravenous (IV) normal saline (typically 1–2 L) is recommended in patients with preserved renal function to promote phosphaturia by increasing urinary flow and inhibiting proximal tubular phosphate reabsorption.^[73] This approach is particularly useful for non-renal causes, such as tumor lysis syndrome or excessive phosphate ingestion, but requires monitoring for fluid overload in those with cardiac or renal compromise.^[72] Loop diuretics may be added if volume status allows, further enhancing renal phosphate clearance.^[1] For patients with AKI, end-stage renal disease (ESRD), or phosphate levels exceeding 10 mg/dL, hemodialysis is the cornerstone intervention, capable of reducing serum phosphate by 50–70% per 4-hour session through diffusive and convective clearance.^[73] In intensive care unit (ICU) settings for hemodynamically unstable patients, continuous renal replacement therapy (CRRT) is preferred per 2025 guidelines, providing steady phosphate removal (up to 30–50 mL/kg/h) while maintaining hemodynamic stability and allowing integration with other supportive therapies.^[72] Peritoneal dialysis offers an alternative but is less efficient for rapid correction.^[1] Discontinuing all exogenous phosphate sources is essential immediately upon diagnosis, including phosphate-containing medications (e.g., laxatives, enemas), supplements, and intravenous preparations, to prevent further accumulation.^[72] In cases of transcellular shifts, such as diabetic ketoacidosis (DKA) or rhabdomyolysis, administration of IV glucose (10–25 g) with insulin (10 units regular insulin) drives phosphate intracellularly via stimulation of Na+/K+-ATPase, typically lowering serum levels by 1–2 mg/dL within hours.^[72] IV calcium supplementation, such as calcium gluconate (1–2 g over 10–20 minutes), is indicated for symptomatic hypocalcemia (e.g., tetany, arrhythmias) secondary to phosphate binding of calcium, but should be avoided if the calcium-phosphate product exceeds 70 mg²/dL² to prevent metastatic calcification.^[73] Close monitoring of serum calcium and phosphate is required during and after administration to guide further dosing.^[1]

Chronic Strategies

Chronic strategies for managing hyperphosphatemia focus on long-term control in patients with chronic kidney disease (CKD), particularly those on dialysis, to prevent complications from persistent phosphate elevation. These approaches emphasize multimodal therapy, including pharmacologic interventions, dietary modifications, and regular monitoring to maintain serum phosphate levels within target ranges. The primary goal is to reduce phosphate absorption and promote excretion while addressing associated secondary hyperparathyroidism (SHPT).^[74] Phosphate binders are a cornerstone of chronic management, administered with meals to bind dietary phosphate in the gastrointestinal tract and prevent its absorption. Calcium-based binders, such as calcium carbonate or acetate, are commonly used but carry risks of hypercalcemia and vascular calcification, leading to recommendations to limit their use in favor of non-calcium alternatives like sevelamer or lanthanum carbonate when possible. According to KDOQI guidelines, the target for predialysis serum phosphate in CKD stage 5D patients is 3.5–5.5 mg/dL (less than 5.5 mg/dL upper limit) to mitigate cardiovascular risks.^[75]^[76] Dietary phosphate restriction is integral, aiming for an intake of 800–1000 mg per day, adjusted for protein needs, to complement binder therapy. Patients are advised to limit high-phosphate foods such as dairy products, nuts, and processed items containing phosphate additives, which can contribute up to 30% of total intake; education on reading labels and choosing plant-based proteins over animal sources enhances compliance. Both KDIGO and KDOQI guidelines endorse this approach as a first-line measure to lower serum phosphate without relying solely on medications.^[74]^[77] Calcimimetics, such as cinacalcet, target the calcium-sensing receptor on parathyroid cells to suppress parathyroid hormone (PTH) secretion, thereby reducing bone resorption of phosphate and improving mineral homeostasis without increasing serum calcium levels. Clinical trials have demonstrated that cinacalcet lowers both PTH and serum phosphate in dialysis patients with SHPT, achieving better control of calcium-phosphate product compared to standard vitamin D analogs alone. It is particularly useful in cases where hyperphosphatemia coexists with elevated PTH.^[78]^[79] Emerging therapies like tenapanor, an intestinal sodium/hydrogen exchanger 3 (NHE3) inhibitor, represent a novel mechanism by inhibiting paracellular phosphate absorption in the gut. Approved by the FDA in October 2023 for reducing serum phosphate in adults with CKD on dialysis as add-on therapy to binders or diet, tenapanor has shown significant reductions in phosphate levels in phase 3 trials, with up to 40% of patients achieving targets when combined with existing regimens.^[80]^[81] Ongoing monitoring is essential, with monthly laboratory assessments of serum phosphate, calcium, PTH, and alkaline phosphatase recommended to guide therapy adjustments and evaluate efficacy. Adherence to phosphate binders and dietary restrictions is challenging, affecting approximately 50% of patients due to pill burden and gastrointestinal side effects, necessitating counseling and simplified regimens to improve outcomes.^[82]^[83] For refractory SHPT with uncontrolled hyperphosphatemia despite medical therapy, parathyroidectomy offers a definitive surgical option. KDIGO guidelines suggest subtotal or total parathyroidectomy with autotransplantation for severe cases in CKD stages 3a–5D, leading to rapid normalization of PTH and phosphate levels in over 80% of patients, though it requires careful postoperative management of hypocalcemia.^[17]^[84]

Prognosis and Complications

Short-Term Outcomes

In acute cases of hyperphosphatemia, resolution is often achieved through prompt removal of the underlying cause, such as in tumor lysis syndrome where rasburicase and aggressive hydration effectively manage electrolyte imbalances including elevated phosphate levels.^[85]^[19] Severe hyperphosphatemia associated with rhabdomyolysis occurs in the context of acute kidney injury, which carries a mortality risk of up to 30%, with rapid intervention such as fluid resuscitation and renal replacement therapy significantly reducing complication rates.^[86] Untreated acute hyperphosphatemia exceeding 10 mg/dL is linked to heightened arrhythmia risk from hypocalcemia and cardiac conduction disruptions.^[4] Dialysis can effectively lower serum phosphate levels in acute settings with preserved underlying renal recovery potential.^[1] In intensive care unit patients, early continuous renal replacement therapy (CRRT) has been associated with improved survival in critically ill individuals with acute kidney injury and hyperphosphatemia.^[87]

Long-Term Risks

Persistent hyperphosphatemia in patients with chronic kidney disease (CKD) significantly elevates the risk of cardiovascular disease (CVD), with studies indicating a 2- to 3-fold increase in CVD mortality among those with CKD stages 3a-4. This heightened risk stems primarily from phosphate-induced vascular calcification, where serum phosphate levels exceeding 3.9 mg/dL promote coronary artery calcification. Furthermore, coronary artery calcification scores serve as a robust predictor of future cardiovascular events in these patients, correlating with accelerated atherosclerosis and left ventricular hypertrophy.^[88] Uncontrolled hyperphosphatemia accelerates CKD progression toward end-stage renal disease (ESRD), with each 1 mg/dL elevation in serum phosphate linked to a 36% greater risk of kidney failure and contributing to a faster glomerular filtration rate (GFR) decline. Analyses highlight that persistent hyperphosphatemia in non-dialysis CKD patients exacerbates renal damage through mechanisms like tubular injury and fibrosis. In the context of CKD-mineral bone disorder (CKD-MBD), including hyperphosphatemia, fracture risk increases 2- to 4-fold by disrupting bone mineralization and promoting high-turnover bone disease.^[89]^[90]^[91] Among dialysis patients, overall 5-year survival is approximately 50%, with uncontrolled hyperphosphatemia contributing to poor prognosis due to compounded cardiovascular and infectious complications. Adherence to phosphate binders and dietary phosphate restriction can mitigate these risks by improving serum phosphate control and associated outcomes through reduced vascular events and better mineral balance. Additionally, chronic symptoms such as pruritus and bone pain, prevalent in up to 40% of affected cases, impair quality of life by fostering depression and sleep disturbances, underscoring the need for integrated symptom management.^[92]^[93]^[94]

References

[1]
Hyperphosphatemia - StatPearls - NCBI Bookshelf - NIH
The most crucial management action is the treatment of the underlying cause. The immediate management involves reducing the phosphate load in the body, either ...
[2]
High Phosphorus (Hyperphosphatemia) - National Kidney Foundation
High phosphorus in the blood is often caused by kidney disease and increases the risk of many health problems. Treatment includes diet changes and medication.
[3]
Hyperphosphatemia: Practice Essentials, Background ...
Jul 11, 2024 · Hyperphosphatemia is considered significant when levels are greater than 5 mg/dL in adults or 7 mg/dL in children or adolescents. (See Workup ...
[4]
Hyperphosphatemia: Causes, Symptoms & Treatment
Oct 14, 2022 · A phosphate level greater than 4.5 milligrams per deciliter (mg/dL) indicates you have hyperphosphatemia. If you have hyperphosphatemia, your ...Missing: elderly | Show results with:elderly
[5]
Phosphate (Phosphorus) - Medscape Reference
Aug 11, 2025 · Adults: 3.0-4.5 mg/dL or 0.97-1.45 mmol/L (SI units) · Older adults: Values slightly lower than those in adults · Children: 4.5-6.5 mg/dL or 1.45- ...
[6]
Phosphorus | Mclendon Clinical Laboratories - Chapel Hill, NC
Dec 26, 2023 · Normal: Serum Phosphorus (mg/dL). Age, Ranges (mg/dL). 0 - 1 year, 4.3-7.3. 1 - 5 years, 4.9-6.5. 5 - 13 years, 4.6-6.2. 13 - 16 years, 3.3-5.8.
[7]
Hyperphosphatemia - Approach to the Patient - DynaMed
Nov 27, 2023 · Hyperphosphatemia is defined as serum phosphate concentration > 4.5 mg/dL (1.45 mmol/L) in adults. The reference range may vary between ...Missing: elderly | Show results with:elderly
[8]
Both hypophosphatemia and hyperphosphatemia are associated ...
Jul 31, 2022 · ... hyperphosphatemia are classified as acute and chronic. Septic patients are essentially acute in onset. Acute hypophosphatemia is more ...
[9]
Renal osteodystrophy: A historical review of its origins and ...
It was as “renal rickets” that a link of bone to kidney disease was first reported in 1883 by a renal surgeon from Guy's Hospital, Richard Clement Lucas (1846– ...
[10]
https://pmc.ncbi.nlm.nih.gov/articles/PMC9713281/
[11]
basics of phosphate metabolism | Nephrology Dialysis Transplantation
This review briefly summarizes our current understanding of the functions, regulation and relevance of phosphate for human health and disease.
[12]
Regulation of Phosphate Homeostasis by PTH, Vitamin D, and FGF23
This review discusses the regulation of phosphate homeostasis by PTH, 1,25(OH) 2 D, and FGF23 with focus on insights gained from human genetic disorders.
[13]
Hyperphosphatemic Familial Tumoral Calcinosis (FGF23, GALNT3 ...
The biochemical hallmark of tumoral calcinosis is hyperphosphatemia caused by increased renal reabsorption of phosphate. This review will summarize the ...
[14]
Phosphate induced crystal acute kidney injury - PubMed Central - NIH
... Fleet enema contains 8.533 g. Such high amounts will produce an almost 100% rise in serum phosphate concentration.8 Finally, renal dysfunction that may have ...
[15]
[PDF] KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis ...
May 31, 2017 · patients with chronic kidney disease on low- and high-calcium diets. Kidney Int. 2012;81:1116–1122. 80. Chonchol M, Locatelli F, Abboud HE ...Missing: tumoral | Show results with:tumoral
[16]
Hyperphosphatemia during nutrition recovery in patients with severe ...
Regarding phosphorus metabolism, the only recognized alteration is hypophosphatemia associated with refeeding syndrome. However, in our clinical practice ...
[17]
Tumor Lysis Syndrome - StatPearls - NCBI Bookshelf
Oct 5, 2024 · Tumor lysis syndrome is a critical medical condition that arises from the rapid breakdown of tumor cells, leading to significant metabolic disturbances.
[18]
Tumor Lysis Syndrome in Patients with Hematological Malignancies
Nov 2, 2017 · The third metabolic abnormalities related to TLS is hyperphosphatemia. Hyperphosphatemia may develop from 24 to 48 hours after treatment. The ...
[19]
Hyperphosphatemia - an overview | ScienceDirect Topics
Hyperphosphatemia is generally defined as a serum phosphate level greater than 5 mg/dL (1.6 mmol/L) in the adult population, whereas children, particularly ...
[20]
Hyperphosphatemia - Endocrine and Metabolic Disorders
Hyperphosphatemia is a serum phosphate concentration > 4.5 mg/dL (> 1.46 mmol/L). Causes include chronic kidney disease, hypoparathyroidism, and metabolic ...Missing: classification | Show results with:classification
[21]
Phosphorus Metabolism Disorders - Cancer Therapy Advisor
Jan 17, 2019 · Shift from intracellular to extracellular compartments. Metabolic acidosis causes phosphorus to shift out of cells. In lactic acidosis, ...Table I · What Tests To Perform? · How To Utilize Team Care?
[22]
Fatal iatrogenic hyperphosphatemia - PubMed
We report an elderly patient with previously normal renal function who developed severe hyperphosphatemia, hypocalcemia, and cardiac arrest.Missing: opioid 2024
[23]
The Risks of Phosphate Enemas in Toddlers: A Life-Threatening ...
Mar 15, 2024 · Phosphate-containing enemas (PcEs) are commonly employed, even causing the risk of rare but lethal toxicity. We investigated pediatricians' awareness of PcE ...
[24]
[PDF] Does sodium phosphate enema use cause electrolyte disorder?
Mar 16, 2024 · They should be used with more caution, especially in patients with underlying gastrointestinal or renal abnormalities.
[25]
Disorders Involving Calcium, Phosphorus, and Magnesium - PMC
The treatment of acute hyperphosphatemia includes volume expansion, dialysis, and oral phosphate binders, although in the setting of normal, or even mild to ...Missing: definition | Show results with:definition
[26]
Secondary Hyperparathyroidism - StatPearls - NCBI Bookshelf
Secondary hyperparathyroidism (SHPT) is an increased secretion of PTH due to parathyroid hyperplasia caused by triggers such as hypocalcemia, hyperphosphatemia ...Introduction · History and Physical · Evaluation · Treatment / Management
[27]
Consequences and management of hyperphosphatemia in patients ...
Hypocalcemia, hyperphosphatemia, and reduced vitamin D seen in patients with CKD are associated with elevated levels of PTH and secondary hyperparathyroidism.
[28]
FGF23 and Vitamin D Metabolism - PMC - PubMed Central
Oct 13, 2021 · Apart from its phosphaturic action, the bone‐derived hormone fibroblast growth factor‐23 (FGF23) is also an essential regulator of vitamin D metabolism.
[29]
Role of FGF23 in vitamin D and phosphate metabolism - PubMed
May 15, 2012 · FGF23 is a bone-derived hormone that regulates systemic phosphate homeostasis, vitamin D metabolism and α-Klotho expression through a novel bone-kidney axis.
[30]
Phosphate in Cardiovascular Disease: From New Insights Into ...
Jan 11, 2024 · Hyperphosphatemia is a common feature in patients with impaired kidney function and is associated with increased risk of cardiovascular disease.Parathyroid Hormone · Dietary Phosphate Exposure... · Intestinal Phosphate...
[31]
Hyperphosphatemia and Cardiovascular Disease - Frontiers
Mar 3, 2021 · Hyperphosphatemia occurs due to a decreasing glomerular filtration rate (GFR) and is known to induce hypertension, vascular calcification, ...<|control11|><|separator|>
[32]
Inflammation-Induced Klotho Deficiency: A Possible Key Driver of ...
May 11, 2025 · A myriad of studies have suggested that inflammation in CKD leads to a decrease in Klotho expression, diminishing Klotho protection capabilities ...
[33]
Calcinosis Cutis - StatPearls - NCBI Bookshelf
Metastatic calcification has abnormal serum levels of calcium and phosphorus with deposition occurring after calcium phosphate product exceeds 70.Calcinosis Cutis · Pathophysiology · Treatment / ManagementMissing: ectopic PO4<|control11|><|separator|>
[34]
Hexasodium Fytate (SNF472 or CSL525) Inhibits Ectopic ... - NIH
Ectopic calcification is a pathological condition characterized by the mineralization of soft tissues due to the abnormal deposition of calcium phosphate ...
[35]
Pulmonary Metastatic Calcifications Secondary to Chronic Renal ...
May 26, 2025 · Metastatic calcification of the lung is linked to various complications, including impaired gas exchange, pulmonary fibrosis, and, in some ...
[36]
The Emerging Role of Phosphate in Vascular Calcification - PMC
Hyperphosphatemia promotes vascular calcification and is a nontraditional risk factor for CVD mortality in ESRD patients.
[37]
Phosphate and Cardiovascular Disease - PMC - PubMed Central
Hyperphosphatemia is a major risk factor for death, cardiovascular events and vascular calcification among patients with and without kidney disease.
[38]
Chronic Kidney Disease-Mineral Bone Disorder (CKD-MBD) - NCBI
Elevated phosphate levels, low calcium levels, and inadequate vitamin D stimulate excessive PTH secretion, leading to bone resorption and calcium release, ...
[39]
Relationship between serum phosphorus and mortality in non ...
Mar 6, 2024 · Hyperphosphatemia is common in chronic kidney disease (CKD), associated with higher mortality in dialysis patients.
[40]
The Pathologic Actions of Phosphate in CKD - PMC - NIH
CKD is associated with high serum levels of phosphate (also called hyperphosphatemia), which is a main driver of soft tissue calcifications and potentially ...
[41]
Soft tissue calcifications in CKD—beyond vasculature
Jun 5, 2025 · Metastatic calcification usually results from an underlying disorder of systemic calcium-phosphate homeostasis and is caused by elevations ...<|separator|>
[42]
Chronic kidney disease-associated pruritus - UpToDate
Jan 6, 2025 · In an international study of over 5500 patients on peritoneal dialysis, the prevalence of moderate to extreme pruritus was 43 percent; the ...
[43]
Factors associated with the severity of pruritus in patients with ...
Jun 23, 2020 · Our study also found that hyperphosphatemia increases the prevalence of severe pruritus, which correlates to other investigations, as well ...
[44]
Consequences and management of hyperphosphatemia in patients ...
Calcium pyrophosphate deposits in the joints of patients with CKD cause arthropathy, crippling joint pain, and swelling accompanied by osteoclast-induced ...
[45]
Hyperphosphatemia - EMCrit Project
Apr 1, 2023 · Hypocalcemia may cause symptoms, for example: Paresthesias (tingling around mouth, hands). Muscle cramping, weakness, laryngospasm.
[46]
Hyperphosphatemia (High Level of Phosphate in the Blood)
Low calcium can cause muscle cramps and spasms but also causes an increase in parathyroid hormone levels, resulting in bone weakness and other problems. The ...
[47]
Hyperphosphatemia Clinical Presentation - Medscape Reference
Jul 11, 2024 · Signs and symptoms of acute hyperphosphatemia result from the effects of hypocalcemia, with patients occasionally reporting symptoms such as muscle cramps, ...
[48]
https://emedicine.medscape.com/article/241185-clinical
[49]
Hyperphosphatemia - an overview | ScienceDirect Topics
Clinical manifestations of severe hyperphosphatemia include nausea, vomiting, diarrhea, lethargy, and seizures.Missing: overload | Show results with:overload
[50]
Phosphorus: A Hidden Challenge in Dialysis
May 7, 2025 · I continued to suffer the effects of high phosphorus, including low energy and brain fog. It was frustrating because my blood levels were ...
[51]
Hypocalcemia - Endocrine and Metabolic Disorders - Merck Manuals
Severe hypocalcemia with serum calcium < 7 mg/dL (< 1.75 mmol/L) may cause hyperreflexia, tetany, laryngospasm, or generalized seizures. Tetany ...
[52]
Uremia: Practice Essentials, Pathophysiology, Etiology
Mar 14, 2024 · Skin: Uremic frost (urea crystals on the skinclassic finding); sallow discoloration or hyperpigmentation (melanosis) as uremia worsens. Eyes ...
[53]
Calciphylaxis - StatPearls - NCBI Bookshelf - NIH
... kidney disease, most cases occur in patients with advanced renal failure. The incidence of calciphylaxis in dialysis patients ranges from 0.04% to 4%, and ...Etiology · Pathophysiology · Evaluation · Treatment / Management
[54]
Clinical Practice Guidelines : Hyperphosphataemia
Causes of hyperphosphataemia ; Increased exogenous phosphate load. Increased endogenous phosphate load or internal redistribution between body compartments.Missing: definition | Show results with:definition
[55]
Renal Osteodystrophy: Review of the Disease and Its Treatment
Secondary hyperparathyroidism represents a common disorder in patients with CKD. It develops as a result of hyperphosphatemia, hypocalcemia and impaired renal ...Secondary... · Adynamic Bone Disease · Treatment Of Renal...<|control11|><|separator|>
[56]
Band Keratopathy Workup: Approach Considerations
Jan 13, 2023 · Renal failure and the need for dialysis can be associated with an elevation in serum phosphate and calcific band keratopathy. If ...Missing: hyperphosphatemia CKD
[57]
Hyperphosphatemia Workup - Medscape Reference
Jul 11, 2024 · Serum phosphate level : Reference range in adults, 2.5-4.5 mg/dL; reference range in children, 3-6 mg/dL; hemolysis or hyperlipidemia of the ...
[58]
Parathyroid Hormone, Phosphorus, Calcium, and Magnesium ...
Apr 30, 2025 · Recommendation 1.4.1 states: “We suggest that point-of-care testing (POCT) may be used for creatinine and urine albumin measurement where access ...
[59]
Fibroblast Growth Factor 23 and Mortality among Patients ...
Increased FGF-23 levels appear to be independently associated with mortality among patients who are beginning hemodialysis treatment.
[60]
https://www.ncbi.nlm.nih.gov/books/NBK476672/
[61]
Hyperphosphatemic Familial Tumoral Calcinosis - NCBI - NIH
Feb 1, 2018 · Deficiency of or resistance to FGF23 leads to hyperphosphatemia resulting in increased renal phosphate reabsorption and elevated or ...
[62]
Targeting Vascular Calcification in Chronic Kidney Disease - JACC
Apr 27, 2020 · The most studied is the Agatston score (39) (often synonymous with “calcium score”) for coronary artery calcification on CT scans. However ...Types Of Calcification · Mechanisms · Therapeutic Approaches
[63]
Cardiovascular calcification in patients with chronic renal failure
In patients without renal insufficiency, a high coronary calcium score (>100) on electron beam computed tomography (EBCT) carries a relative risk for future ...Missing: MRI | Show results with:MRI
[64]
Bone Biopsy for Histomorphometry in Chronic Kidney Disease (CKD)
Oct 8, 2021 · Bone biopsy is indicated to confirm the diagnosis of subclinical or focal osteomalacia and to characterize the different forms of renal osteodystrophy (ROD).Missing: hyperphosphatemia | Show results with:hyperphosphatemia
[65]
Phosphorus inorganic (Unit Conversion) :: MediCalc®
Phosphorus inorganic. nl values: Phosphorus inorganic (S)= 3 - 4.5 mg/dL (0.97 - 1.45 mmol/L) CF: 0.3229. Molecular Weight: 31. CF= conversion factor. Multiply ...
[66]
Phosphorus blood test - UCSF Benioff Children's Hospitals
Nov 19, 2023 · Normal values range from: Adults: 2.8 to 4.5 mg/dL; Children: 4.0 to 7.0 mg/dL. Normal value ranges may vary slightly among different ...
[67]
Hypocalcaemia - ECG Library - LITFL
Oct 8, 2024 · Hypocalcaemia causes QTc prolongation primarily by prolonging the ST segment · The T wave is typically left unchanged · Dysrhythmias are uncommon, ...Missing: hyperphosphatemia | Show results with:hyperphosphatemia
[68]
Association Between Disturbed Serum Phosphorus Levels and QT ...
Decreased serum Ca levels and decreased and increased serum P levels may be associated with QT interval prolongation in patients on maintenance HD.
[69]
Pseudohyperphosphatemia in multiple myeloma - PubMed
Sep 15, 2025 · Background Multiple myeloma patients may present with spuriously elevated serum phosphate levels resulting from the presence of paraproteins ...
[70]
https://kdigo.org/wp-content/uploads/2025/02/KDIGO-2025-CKD-MBD-Controversies-Conference-Report_Final.pdf
[71]
[PDF] Chronic kidney disease-mineral and bone disorder - KDIGO
25-(OH)D, 25-hydroxyvitamin D; CKD, chronic kidney disease; CPP, calciprotein particle; DXA, dual-energy X-ray absorptiometry; FGF23, fibroblast growth factor ...
[72]
[PDF] Evaluating Osteoporosis in Chronic Kidney Disease: Both Bone ...
Feb 9, 2024 · Patients with chronic kidney disease (CKD) have a higher risk of fractures than the general population, and the incidence of fractures increases ...
[73]
Overview of the causes and treatment of hyperphosphatemia
Mar 17, 2025 · Acute phosphate nephropathy · Acute extracellular shift of phosphate · Acute or chronic kidney disease · Increased tubular reabsorption of ...
[74]
Hyperphosphatemia Treatment & Management - Medscape Reference
Jul 11, 2024 · Administration of phosphate binders is the only truly long-term therapy for chronic hyperphosphatemia due to kidney failure.Missing: AKI | Show results with:AKI
[75]
Strategies for Phosphate Control in Patients With CKD - PMC
The KDOQI guidelines of 2011 suggested that phosphate levels should be kept between 3.5 and 5.5 mg/dl, whereas the subsequent KDIGO guideline of 2009 and its ...
[76]
Phosphorus binders: The new and the old, and how to choose
Aug 1, 2018 · This review describes the pathophysiology and control of hyperphosphatemia and the different classes of phosphorus binders with respect to their availability, ...Phosphorus Balance · Phosphorus Binders · Calcium-Free Binders
[77]
An introduction to phosphate binders for the treatment of ...
Phosphate binders to absorb excess ingested phosphate, can help to maintain serum phosphate levels near the recommended concentration of 5.5 mg/dL.
[78]
4 - NKF KDOQI Guidelines
4.1 Dietary phosphorus should be restricted to 800 to 1,000 mg/day (adjusted for dietary protein needs) when the serum phosphorus levels are elevated (>4.6 ...
[79]
Cinacalcet for Secondary Hyperparathyroidism in Patients ...
Apr 8, 2004 · Cinacalcet lowers parathyroid hormone levels and improves calcium–phosphorus homeostasis in patients receiving hemodialysis who have uncontrolled secondary ...
[80]
Effects of the calcimimetic cinacalcet HCl on cardiovascular disease ...
Cinacalcet, a calcimimetic that modulates the calcium-sensing receptor, reduces parathyroid hormone (PTH) secretion and lowers serum calcium and phosphorus ...
[81]
FDA Approves XPHOZAH® (tenapanor), a First-in-Class Phosphate ...
Oct 17, 2023 · XPHOZAH has been approved to reduce serum phosphorus in adults with chronic kidney disease (CKD) on dialysis as add-on therapy.
[82]
[PDF] XPHOZAH (tenapanor) - accessdata.fda.gov
XPHOZAH is indicated to reduce serum phosphorus in adults with chronic kidney disease (CKD) on dialysis as ... hyperphosphatemia is unknown. All ...
[83]
Hyperphosphatemia in Chronic Kidney Disease - Dove Medical Press
May 28, 2024 · Klotho deficiency, which appears to be one of the first alterations found in CKD-MBD, determines resistance to the action of FGF23, which ...<|control11|><|separator|>
[84]
Phosphate-control adherence in hemodialysis patients: current ...
This review summarizes factors relevant for adherence to phosphate-control strategies in dialysis patients, and discusses interventions to overcome related ...
[85]
Parathyroidectomy in the Management of Secondary ... - NIH
Mar 9, 2018 · In these guidelines, parathyroidectomy is suggested for patients with all stages of CKD ranging from early eGFR decline <60 ml/min per 1.73 m2 ...
[86]
Rasburicase in treating tumor lysis syndrome: An umbrella review
The response rate for rasburicase reported in retrospective and prospective studies (effect ratio [ER]) was 0.87 (95% CI = 0.82–0.93). Figure 3. Figure 3.
[87]
How I Treat Rhabdomyolysis-Induced AKI? - PMC - NIH
Older age and comorbidity are risk factors of rhabdomyolysis-induced AKI, which associates with prolonged hospitalization, high mortality (up to 30%), and ...
[88]
Time to CRRT Initiation and 90-Day Major Adverse Kidney Events in ...
Jan 2, 2024 · These results suggest that delaying initiation of CRRT in children who are critically ill was associated with an increased risk of adverse events.Missing: hyperphosphatemia | Show results with:hyperphosphatemia
[89]
Hyperphosphatemia and Cardiovascular Disease - PMC - NIH
Mar 4, 2021 · Hyperphosphatemia is defined as plasma phosphate >4.5 mg/dL due to disease or excessive intake. Excessive phosphate content not only causes ...
[90]
High Phosphorus Levels Predict CKD Progression, Early Death
Aug 26, 2015 · Every 1 mg/dL increase in serum phosphorus level was independently associated with 36% greater risk of kidney failure and 20% greater risk of ...
[91]
Hyperphosphatemia in Kidney Failure: Pathophysiology ... - MDPI
Hyperphosphatemia is independently associated with dire consequences, including bone and mineral disease, high risk of CV disease, and mortality [105,106,107].Hyperphosphatemia In Kidney... · 2. Phosphate Homeostasis · 2.3. Renal Phosphate...
[92]
Serum phosphate is associated with increased risk of bone fragility ...
Mar 27, 2024 · Hyperphosphatemia was independently and consistently associated with an increased bone fracture risk, suggesting serum phosphate could be a novel risk factor.
[93]
Phosphate Control: The Next Frontier in Dialysis Cardiovascular ...
Jun 11, 2021 · These rates are higher than those of some cancers; the unadjusted probability of 5-year survival is ∼50% in patients with dialysis compared to ...
[94]
Effect of Phosphate-Specific Diet Therapy on Phosphate Levels in ...
Dec 30, 2020 · Monthly diet therapy (20–30 minutes) significantly lowered serum phosphate in patients with persistent hyperphosphatemia for 4–6 months, without compromising ...
[95]
Chronic kidney disease-associated pruritus: impact on quality of life
Jan 23, 2017 · It affects ~40% of patients with end-stage renal disease and has been associated with poor quality of life, poor sleep, depression, and mortality.